Exagen Inc. to Announce Fourth Quarter and Full-Year 2024 Financial Results on March 11, 2025
February 25 2025 - 3:05PM
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune
testing, will release financial results for the quarter and year
ended December 31, 2024, before the market opens on Tuesday, March
11, 2025. John Aballi, Exagen’s President and Chief Executive
Officer, and Jeff Black, Chief Financial Officer, will host a
conference call to review the company’s results at 8:30 AM ET (5:30
AM PT).
Interested parties may access the conference call by dialing
201-389-0918 (U.S.) or +1-877-407-0890 (international).
Participants wishing to access the call via webcast should use the
link posted on the Exagen investor relations website at
investors.exagen.com.
A replay of the conference call will be available until Monday,
April 14, 2025, at 11:59 PM ET (8:59 PM PT). Interested parties may
access the replay by dialing 201-612-7415 (U.S.) or +1-877-660-6853
(international) using passcode 13751928. Additionally, a recording
of the webcast will be available using the link on the Exagen
investor relations website approximately one hour after the call
concludes.
About Exagen Inc.
Exagen Inc. (Nasdaq: XGN) is a leading provider of autoimmune
diagnostics, committed to transforming care for patients with
chronic and debilitating autoimmune conditions. Based in San Diego
County, California, Exagen’s mission is to provide clarity in
autoimmune disease decision making and improve clinical outcomes
through its innovative testing portfolio. The company’s flagship
product, AVISE® CTD, enables clinicians to more effectively
diagnose complex autoimmune conditions such as lupus, rheumatoid
arthritis, and Sjögren’s syndrome earlier and with greater
accuracy. Exagen’s laboratory specializes in the testing of
rheumatic diseases, delivering precise and timely results,
supported by a full suite of AVISE-branded tests for disease
diagnosis, prognosis, and monitoring. With a focus on research,
innovation, education, and patient-centered care, Exagen is
dedicated to addressing the ongoing challenges of autoimmune
disease management.
For more information, visit Exagen.com or follow @ExagenInc on
X.
Contact:Ryan DouglasExagen
Inc.ir@exagen.com760.560.1525
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Jan 2025 to Feb 2025
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Feb 2024 to Feb 2025